StreetAlpha.app
Home › Stocks › RCEL

AVITA Medical, Inc. (RCEL)

Healthcare
$15.62
▼ −2.31%
LAST CLOSE · NOV 20

AVITA Medical sells RECELL, a skin cell device for wound care, plus PermeaDerm and Cohealyx wound matrices to burn and trauma centers. It last closed at $15.62 on Nov 20, down 2.31% on the day. The next earnings report for RCEL is expected around Tue, Jan 12, 2027. For the quarter ended Sep 2026, RCEL reported EPS of -$0.20 on revenue of $26.1M, with revenue up 53.1% from a year ago. Over its last 8 reports the stock moved an average of 18.3% the session after earnings. Over the last 12 months RCEL insiders bought $227K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is RCEL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RCEL.

Key Stats

Last 12 months
Results
Revenue
$84.7M
+17.0% vs a year ago
Net income
−$36.1M
−42.7% margin
EPS (diluted)
−$1.17
Free cash flow
−$20.2M
−23.8% margin
Valuation
Market cap
$490.8M
31.4M shares
P/E
–
No P/E while losing money
Price to sales
5.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.5M
At Sep 30
Debt
$45.5M
At Sep 30
Shareholder equity
−$31.0M
Shares outstanding
31.4M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $29.2M$29.2MFY2021FY2022: $34.4M$34.4MFY2022FY2023: $50.1M$50.1MFY2023FY2024: $64.3M$64.3MFY2024FY2025: $71.6M$71.6MFY2025

From RCEL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 12
Estimated date · Time not announced
Reported EPS
-$0.20
Quarter ended Sep 2026
Year ago EPS
-$0.46
Same quarter last year
Revenue
$26.1M
+53.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.44Dec '24Mar 2025: -$0.53Mar '25Jun 2025: -$0.38Jun '25Sep 2025: -$0.46Sep '25Dec 2025: -$0.37Dec '25Mar 2026: -$0.35Mar '26Jun 2026: -$0.25Jun '26Sep 2026: -$0.20Sep '26Latest -$0.20
Revenue by quarter
Dec 2024: $18.4MDec '24Mar 2025: $18.5MMar '25Jun 2025: $18.4MJun '25Sep 2025: $17.1MSep '25Dec 2025: $17.6MDec '25Mar 2026: $19.3MMar '26Jun 2026: $21.7MJun '26Sep 2026: $26.1MSep '26Latest $26.1M
How RCEL moved after its last 8 reports
Average move the session after a report ±18.3%
Nov 5, 2026After the close+5.8%
Aug 6, 2026After the close+63.6%
May 14, 2026After the close+4.6%
Feb 12, 2026After the close+11.8%
Jan 13, 2026Time not announced−3.5%
Nov 6, 2025After the close+10.9%
Aug 7, 2025After the close−21.0%
May 8, 2025After the close−25.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RCELStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RCEL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RCEL

Technical Analysis

RCEL · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 52% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 51). The nearest support is the Pivot S1 at $15.33, and the nearest resistance the Pivot at $15.79.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 7.8%/day
Key levels
$18.4352 week high+18.0%
$16.90Swing high (Oct 29)+8.2%
$16.1420 day average+3.3%
$16.09Pivot R1+3.0%
$15.79Pivot+1.1%
$15.62Last close
$15.33Pivot S1−1.9%
$14.74Swing low (Nov 16)−5.6%
$13.9650 day average−10.6%
$10.55100 day average−32.5%
$7.45200 day average−52.3%
$3.2252 week low−79.4%
Indicators
RSI (14)51.49Middle of its rangeNeutral
MACD0.57Below its signal lineBearish
Stochastic38.8Middle of its rangeNeutral
ADX (14)28.7Trending up
Williams %R-76.2Oversold below −80, overbought above −20Neutral
CCI (20)-44.0Oversold below −100, overbought above 100Neutral
Rate of change−5.8%Change over 10 sessionsBearish
ATR (14)$1.21Typical daily range, 7.8% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for RCEL

What happened before

See how RCEL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RCEL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RCEL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RCELHow many large options trades hit RCEL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

RCEL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲59 buying vs 39 selling
  • ▲Held by funds +13.8 pts
  • ▲Funds holding +16
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8973+21.9%
In funds' top 1000–
Held by funds29.5%15.7%+13.8 pts
New / increased33 / 2620 / 25+31.1%
Reduced / sold out22 / 1720 / 24−11.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RCEL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RCEL Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$227K8 buys · 2 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $206K between May 19 and Jun 9.
2026-02 bought $12K2026-03 bought $9K2026-05 bought $17K2026-06 bought $189KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 9Joseph Fralin WoodyDirectorBuy5,200$4.00$21K
Jun 9Joseph Fralin WoodyDirectorBuy10,000$4.19$42K
Jun 3Joseph Fralin WoodyDirectorBuy10,000$4.09$41K
Jun 2Joseph Fralin WoodyDirectorBuy20,000$4.25$85K
May 20David D O'TooleCFOBuy2,000$4.26$9K
May 19David D O'TooleCFOBuy2,000$4.24$8K
Every insider buy and sale for RCEL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RCEL insider trades →

From SEC Form 4 filings by RCEL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCEL is in one of them and how their past RCEL trades turned out.

RCEL in the AI portfolios
Loading…

RCEL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RCEL in an article yet. Here's the latest on the wider market.

RCEL in the news

About AVITA Medical

AVITA Medical is an acute wound care company based in Valencia, California. Its main product is RECELL, a device that lets clinicians prepare a suspension of a patient's own skin cells at the point of care, which can cover large wounds using a small donor skin sample. The company also sells PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a dermal matrix made from collagen. Its customers are mainly burn, trauma and surgical centers, chiefly in the United States.

Headquarters
Valencia, CA
Founded
1993